Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

H. C. Diener*, R. Bernstein, K. Butcher, B. Campbell, G. Cloud, A. Davalos, S. Davis, J. M. Ferro, M. Grond, D. Krieger, G. Ntaios, A. Slowik, E. Touzé

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

Original languageEnglish (US)
Pages (from-to)9-12
Number of pages4
JournalInternational Journal of Stroke
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • Ischemic stroke
  • dabigatran
  • idarucizumab
  • rt-PA
  • thrombectomy
  • thrombolysis

ASJC Scopus subject areas

  • Neurology

Fingerprint Dive into the research topics of 'Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion'. Together they form a unique fingerprint.

Cite this